NEO beat EPS expectations by 296.83%
Nov 05, 2024, 5:33 PM
0.00%
What does NEO do
NeoGenomics, a clinical laboratory company based in Fort Myers, Florida, specializes in cancer genetics diagnostic testing and pharma services, employing 2,100 staff since its IPO in December 2012. Its services include clinical cancer testing and advanced diagnostics for healthcare providers and pharmaceutical companies.
Neogenomics (NEO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Neogenomics's actual EPS was $0.05, beating the estimate of $0.01 per share, resulting in a 296.83% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.